Key facts
- This page summarizes Christopher Paul German's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 19 May 2026, 16:15.
Christopher Paul German - 15 May 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)
- Reporting relationship
- Corporate Controller & CAO
- Issuer ticker
- RYTM
- Reported as of
- 15 May 2026
- Net transaction value
- -$428,131
- SEC form
- 4
- Accepted by SEC
- 19 May 2026, 16:15:19 UTC
- Prior SEC filing
- 06 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Paul German filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 19 May 2026.
Change
- Previous filing in this sequence was filed on 06 Mar 2026.
- Current net transaction value: -$428,131.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001260835
Primary reporting owner
German Christopher Paul
- Relationship
- Corporate Controller & CAO
- Address
- 222 BERKELEY STREET, 12TH FLOOR, BOSTON
- Signature
- /s/ Stephen Vander Stoep, attorney-in-fact for Christopher Paul German
- Signature date
- 19 May 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RYTM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,687
- Change %
- +839%
- Price
- $56.69*
- Shares after
- 1,888
- Date
- 15 May 2026
- Ownership
- Direct
- Footnotes
- F1
RYTM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,349
- Change %
- +71%
- Price
- $49.23*
- Shares after
- 3,237
- Date
- 15 May 2026
- Ownership
- Direct
RYTM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,406
- Change %
- +43%
- Price
- $17.97*
- Shares after
- 4,643
- Date
- 15 May 2026
- Ownership
- Direct
RYTM
transaction
Common Stock
Sale
- Transaction value
- $428,131
- Shares
- -4,643
- Change %
- -100%
- Price
- $92.21
- Shares after
- 0
- Date
- 15 May 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RYTM
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -1,687
- Change %
- -31%
- Price
- $0.000000*
- Shares after
- 3,713
- Date
- 15 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,687
- Exercise price
- $56.69
- Footnotes
- F2
RYTM
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -1,349
- Change %
- -33%
- Price
- $0.000000*
- Shares after
- 2,701
- Date
- 15 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,349
- Exercise price
- $49.23
- Footnotes
- F3
RYTM
transaction
Derivative
Stock Options (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -1,406
- Change %
- -38%
- Price
- $0.000000*
- Shares after
- 2,325
- Date
- 15 May 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,406
- Exercise price
- $17.97
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Includes an aggregate of 201 shares of Common Stock purchased pursuant to the Rhythm Pharmaceuticals, Inc. Employee Stock Purchase Plan.
Footnote F2
The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Footnote F3
The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Footnote F4
The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date.